Mayo Clinic proceedings
-
Mayo Clinic proceedings · Jun 2022
Meta AnalysisNewer P2Y12 Inhibitors vs Clopidogrel in Acute Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock: A Systematic Review and Meta-analysis.
To evaluate the outcomes, safety, and efficacy of dual antiplatelet therapy (DAPT) with newer P2Y12 inhibitors compared with clopidogrel in patients with acute myocardial infarction (AMI) complicated by cardiac arrest (CA) or cardiogenic shock (CS). ⋯ In patients with AMI-CA/CS receiving DAPT, compared with clopidogrel, newer P2Y12 inhibitors were associated with lower rates of early and 1-year mortality. Data on major bleeding and stent thrombosis were inconclusive.
-
Mayo Clinic proceedings · Jun 2022
Shift Work, Genetic Factors, and the Risk of Heart Failure: A Prospective Study of the UK Biobank.
To quantify the association of combined shift work and genetic factors with the incidence of heart failure (HF). ⋯ Shift work, particularly permanent night shift work, may increase the risk of HF in females, especially in those with high genetic risk.
-
Mayo Clinic proceedings · Jun 2022
Outcomes of Patients With Type 2 Myocardial Infarction Complicating Acute Ischemic Stroke.
To study the patient profiles and the prognostic impact of type 2 myocardial infarction (MI) on outcomes of acute ischemic stroke (AIS). ⋯ Type 2 MI in patients hospitalized with AIS is associated with poor prognosis and higher resource utilization.
-
Mayo Clinic proceedings · Jun 2022
Prevalence and Natural History of Mitral Annulus Calcification and Related Valve Dysfunction.
To evaluate the prevalence and natural history of mitral annulus calcification (MAC) and associated mitral valve dysfunction (MVD) in patients undergoing clinically indicated echocardiography. ⋯ In a large cohort of adults undergoing echocardiography, the prevalence of MAC was 23%. Mitral valve dysfunction was more than twice as prevalent in patients with MAC. Adjusted mortality was increased in patients with MAC and worse with both MAC and MVD.
-
Mayo Clinic proceedings · Jun 2022
Ultra-Low-Dose Systemic Tissue Plasminogen Activator in High-Risk Submassive Pulmonary Embolism.
Risk stratification of pulmonary embolism (PE) is vital for clinical management. While low-risk and high-risk PE management are clearly defined in many societal guidelines, the management of moderate-risk, also called submassive, PE remains unsettled. ⋯ The role of thrombolysis in the management of submassive PE remains to be established. We share our experience with ultra-low-dose (25-mg) systemic tissue plasminogen activator in a series of 4 patients with high-risk submassive PE.